Since the utilization of Survivin-T34A by adenoviral vectors showed moderate therapeutic results [91], Aspe et al. treated MIA PaCa-2 cell lines with Survivin-T34A-enriched exosomes raised by engineered melanoma cells. This evidence concerns the gene BIRC5 and melanoma.